Transcutaneous auricular vagus nerve stimulation for functional dyspepsia: A systematic review and meta-analysis.

Functional dyspepsia causes chronic stomach discomfort, pain, and bloating that isn't linked to an identifiable disease. Researchers reviewed six studies involving 716 patients to evaluate whether transcutaneous auricular vagus nerve stimulation (taVNS)—a noninvasive treatment using electrical stimulation on specific ear points—could help manage this condition.

The studies compared taVNS to sham (fake) treatments or used it alongside standard medications. Treatments typically involved stimulating the concha or tragus areas of the ear at frequencies of 20-25 Hz, twice daily for 2-4 weeks. This approach shares similarities with auricular acupuncture, which also targets specific ear points to influence body function.

The results were promising. Patients receiving taVNS experienced significant improvements in stomach symptoms compared to those receiving sham treatment. Quality of life also improved, and patients reported reduced anxiety and depression. When taVNS was added to conventional medication, it enhanced symptom relief beyond medication alone. The overall treatment effectiveness rate was notably higher with taVNS, and no serious side effects were reported.

Researchers explored how taVNS works by measuring gastric function, heart rate patterns, and brain activity. The evidence quality was rated as moderate to high, suggesting these findings are reasonably reliable.

What this means: If you have functional dyspepsia that hasn't responded well to standard treatments, ear-based electrical stimulation or auricular acupuncture may offer relief for digestive symptoms, anxiety, and overall well-being without significant risks. To explore acupuncture or related therapies for digestive issues, seek a licensed acupuncturist with experience treating gastrointestinal conditions.

This systematic review and meta-analysis evaluated transcutaneous auricular vagus nerve stimulation (taVNS) for functional dyspepsia across six RCTs (n=716). Primary outcomes assessed dyspepsia symptom improvement; secondary outcomes included total effective rate (TER), quality of life, anxiety, and depression scores. GRADE methodology determined evidence certainty.

Findings demonstrated that taVNS significantly improved dyspepsia symptoms versus sham intervention with moderate certainty evidence. TER showed significant improvement with high certainty evidence. Quality of life and clinician-rated anxiety and depression scores improved significantly with moderate certainty. When used as adjunctive therapy, taVNS enhanced symptom relief with moderate certainty evidence. No serious adverse events were reported.

Stimulation protocols typically targeted the concha and tragus at 25 or 20 Hz, twice daily for 2-4 weeks. Mechanistic investigations included gastric accommodation, electrogastrogram, HRV, and fMRI measurements.

Clinical takeaway: taVNS represents a safe, evidence-based noninvasive intervention for functional dyspepsia, improving symptoms and psychological comorbidities. Additional research should establish optimal treatment parameters.